Newsletters

[Science] Researchers identified aberrant epithelial cell death as a hallmark of IBD that emerges early in lesions, persists despite advanced therapies, and predicts disease relapse.

[Acta Biomaterialia] Scientists developed an immune-activated co-culture model comprising patient-derived gastric cancer organoids and autologous peripheral blood mononuclear cells as a framework for personalized chemotherapy screening strategies.

[Gut Microbes] The authors found that Agathobacter rectalis (Ar) suppressed colorectal cancer cell growth, clonogenicity, migration, and cell cycle progression. They identified (−)-epigallocatechin (EGC) as an Ar-derived metabolite that recapitulated Ar-mediated anti-CRC effects, defining an Ar–EGC microbe–metabolite axis.

[Clinical and Translational Medicine] Researchers revealed a cysteine dioxygenase type 1 (CDO1)–PI3K/AKT–THBS1 signalling axis that supports CDO1-mediated tumour suppression in gastric cancer.

[Redox Report] The authors investigated the molecular mechanisms underlying oxidative damage to the intestinal barrier and intestinal epithelial cell toxicity by the natural co-occuring pollutants, Cr(VI) and DON, using the network toxicology method and cell intervention experiments.

[Biomolecules & Therapeutics] Scientists examined the methylation-dependent regulation of the miR-124–KITENIN axis and its clinical significance in colorectal cancer using a diverse panel of human cell lines.

[Nature Reviews Gastroenterology & Hepatology] The authors summarize the latest advances and current knowledge gaps from within the Intestinal Stem Cell Consortium working group and across the field as a whole to understand the intestinal stemm cell niche, stem cell interactions with and in response to pathogens, and cellular and humoral regenerative strategies.

[Autoimmunity Reviews] Scientists discuss extracellular vesicles as key regulators of intestinal homeostasis and inflammatory responses, offering new insights into the pathogenesis of inflammatory bowel disease and the development of targeted therapeutic strategies.

[Biochemical Pharmacology] The authors systemically summarize the basic biological features of the cAMP response element modulator, which comprises structural characteristics, isoform diversity, and regulatory networks in cellular signaling.

[BeOne Medicines] The FDA has approved BeOne Medicines's TEVIMBRA^® (tislelizumab) in combination with ZIIHERA^® (zanidatamab) and chemotherapy for the first-line treatment of adult patients with HER2-positive (HER2+) gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA).

[BigHat Biosciences] The first patient has been dosed in BigHat Biosciences' Phase 1 clinical trial evaluating BHB810, a novel, potentially best-in-class Cadherin-17 (CDH17)-directed VHH-Fc antibody-drug conjugate for the treatment of gastric cancer and other advanced gastrointestinal malignancies.

[Allergy] The authors investigated the molecular and functional consequences of sodium dodecyl sulfate and cocamidopropyl betaine exposure in primary eosinophilic esophagitis-derived esophageal organoids and air-liquid interface cultures derived from biopsy tissue samples.